← Home
Mid-America Apartment Communities 
Real estate / REIT Apartments
📢 Press Releases
| Date | Press release |
|---|---|
| 2025-05-20 16:15:00 | Maa Announces Quarterly Common Dividend Germantown, tenn. , may 20, 2025 /prnewswire/ -- mid-america apartment communities, inc., or maa (nyse: maa), today announced that its board of directors approved a quarterly dividend payment of $1.5150 per share of common stock to be paid on july 31, 2025, to shareholders of record on july 15, 2025. |
| 2025-04-30 16:15:00 | Maa Reports First Quarter 2025 Results Germantown, tenn. , april 30, 2025 /prnewswire/ -- mid-america apartment communities, inc., or maa (nyse: maa), today announced operating results for the three months ended march 31, 2025. |
| 2025-04-02 16:15:00 | Maa Announces Date Of First Quarter Earnings Release, Conference Call Germantown, tenn. , april 2, 2025 /prnewswire/ -- maa (nyse: maa) announced today that the company expects to release its first quarter 2025 results on wednesday, april 30, 2025, after market close and will hold a conference call on thursday, may 1, 2025, at 9:00 a.m. |
| 2025-03-27 16:05:00 | Crinetics Pharmaceuticals Announces European Medicines Agency (ema) Validation Of Marketing Authorization Application (maa) And Orphan Drug Designation (odd) For Paltusotine In Acromegaly San diego, march 27, 2025 (globe newswire) -- crinetics pharmaceuticals, inc. (nasdaq: crnx) today announced that the european medicines agency (ema) has validated the marketing authorization application (maa) for paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the proposed treatment and long-term maintenance therapy of acromegaly, a serious, rare and progressive endocrine disorder characterized by consistently elevated levels of growth hormone. the maa will now be reviewed by the committee for medicinal products for human use (chmp). additionally, the ema on february 27, 2025 granted paltusotine orphan drug designation (odd) for the treatment of acromegaly. |
| 2025-03-25 07:30:00 | Fda Grants Priority Review For Biologics License Application (bla) And Ema Accepts Marketing Authorisation Application (maa) For Apitegromab As A Treatment For Spinal Muscular Atrophy Cambridge, mass.--(business wire)--scholar rock (nasdaq: srrk), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the u.s. food and drug administration (fda) has accepted its biologics license application (bla) for apitegromab, an investigational muscle-targeted treatment that is being developed to provide clinically meaningful improvement in motor function for. |
| 2025-03-18 16:15:00 |
|
| 2025-03-03 16:15:00 |
|
| 2025-02-28 16:15:00 |
|
| 2025-02-05 16:15:00 |
|
| 2025-01-21 06:45:00 |
|
| 2025-01-16 16:15:00 |
|
| 2024-12-11 16:27:00 |
|
| 2024-12-10 16:30:00 |
|
| 2024-12-02 16:15:00 |
|
| 2024-10-30 16:15:00 |
|
📰 Browse additional press releases for Mid-America Apartment Communities!
Sign up for free or log in💡 Learn smarter stock picks with "The Checklist Value Investor — A Smarter Way to Pick Stocks"